Literature DB >> 10882053

Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet].

L Steinman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10882053     DOI： 10.1006/jaut.2000.0379

Source DB:  PubMed          Journal:  J Autoimmun        ISSN： 0896-8411            Impact factor:   7.094


× No keyword cloud information.
  4 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

2.  Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis.

Authors:  Elisabeth Calderón-Gómez; Vicky Lampropoulou; Ping Shen; Patricia Neves; Toralf Roch; Ulrik Stervbo; Sascha Rutz; Anja A Kühl; Frank L Heppner; Christoph Loddenkemper; Stephen M Anderton; Jean M Kanellopoulos; Pierre Charneau; Simon Fillatreau
Journal:  Eur J Immunol       Date:  2011-05-25       Impact factor: 5.532

3.  T cells that trigger acute experimental autoimmune encephalomyelitis also mediate subsequent disease relapses and predominantly produce IL-17.

Authors:  Jinzhu Li; Xiaoqing Zhao; Hui-Wen Hao; Michael K Shaw; Harley Y Tse
Journal:  J Neuroimmunol       Date:  2010-09-09       Impact factor: 3.478

4.  Robust immunoreactivity of teenager sera against peptide 19 from Porphyromonas gingivalis HSP60.

Authors:  Eun-Young Kwon; Gil Sun Cha; Ji-Young Joo; Ju-Youn Lee; Jeomil Choi
Journal:  J Periodontal Implant Sci       Date:  2017-06-28       Impact factor: 2.614
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.